Premium
Results of combined modality therapy for patients with anal cancer (E7283). An eastern cooperative oncology group study
Author(s) -
Martenson James A.,
Lipsitz Stuart R.,
Lefkopoulou Myrto,
Engstrom Paul F.,
Dayal Yogeshwar Y.,
Cobau Charles D.,
Oken Martin M.,
Hatter Daniel G.
Publication year - 1995
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19951115)76:10<1731::aid-cncr2820761009>3.0.co;2-h
Subject(s) - medicine , anal cancer , oncology , modality (human–computer interaction) , clinical oncology , cancer , treatment modality , artificial intelligence , computer science
Background . This prospective study assessed combined modality therapy of patients with International Union Against Cancer classification T1‐4 NO MO anal cancer. Methods . Protocol therapy consisted of a dose of 4000 cGy to the pelvis, anus, and perineum, followed by a 1000‐1300 cGy boost. Infusions of 5‐fluorouracil and mitomycin‐C were administered when radiation therapy began. A second infusion of 5‐fluorouracil was administered 28 days later. Biopsy was performed 6‐8 weeks after completion of treatment. Positive biopsy findings resulted in abdominal‐perineal resection. Results . Survival at 7 years for 50 eligible patients was 58%. White patients and those with favorable performance status had significantly better survival. Of the 46 patients evaluable for response, 34 had a complete response, 11 had a partial response, and I had no response. Seven‐year survival for partial responders was 53%. Freedom from locoregional progression was 80% at 7 years. Conclusion . Treatment with a combination of chemotherapy and radiation therapy is effective for patients with anal cancer. The investigation of methods of improving therapy is warranted. Cancer 1995; 76:1731–6.